Literature DB >> 22750587

Clavulanic acid inhibits MPP⁺-induced ROS generation and subsequent loss of dopaminergic cells.

Gina Chun Kost1, Senthil Selvaraj, Young Bok Lee, Deog Joong Kim, Chang-Ho Ahn, Brij B Singh.   

Abstract

Clavulanic acid is a psychoactive compound that has been shown to modulate central nervous system activity. Importantly, in neurotoxin-induced animal models, clavulanic acid has been shown to improve motor function (Huh et al., 2010) suggesting that it can be neuroprotective; however, the mechanism as how clavulanic acid can induce neuroprotection is not known. We demonstrate here that clavulanic acid abrogates the effects of the neurotoxin 1-methyl-4-phenylpyridinium (MPP(+)) which mimics Parkinson's disease (PD) by inducing neurodegeneration. To further establish the mechanism we identified that clavulanic acid inhibits neurotoxin-induced loss of mitochondrial membrane potential and ROS production. Consistent with these results, neurotoxin-induced increase in Bax levels was also decreased in clavulanic acid treated cells. Importantly, neurotoxin-induced release of cytochrome c levels as well as caspase activation was also inhibited in clavulanic acid treated cells. In addition, Bcl-xl levels were also restored and the Bcl-xl/Bax ratio that is critical for inducing apoptosis was increased in clavulanic acid treated cells. Overall, these results suggest that clavulanic acid is intimately involved in inhibiting neurotoxin-induced loss of mitochondrial function and induction of apoptosis that contributes towards neuronal survival.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22750587      PMCID: PMC3628769          DOI: 10.1016/j.brainres.2012.06.005

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  25 in total

Review 1.  Mitochondria as the central control point of apoptosis.

Authors:  S Desagher; J C Martinou
Journal:  Trends Cell Biol       Date:  2000-09       Impact factor: 20.808

Review 2.  Parkinson's disease.

Authors:  Ali Samii; John G Nutt; Bruce R Ransom
Journal:  Lancet       Date:  2004-05-29       Impact factor: 79.321

Review 3.  Biochemical pathways of caspase activation during apoptosis.

Authors:  I Budihardjo; H Oliver; M Lutter; X Luo; X Wang
Journal:  Annu Rev Cell Dev Biol       Date:  1999       Impact factor: 13.827

Review 4.  MPTP: current concepts and controversies.

Authors:  J W Langston; I Irwin
Journal:  Clin Neuropharmacol       Date:  1986       Impact factor: 1.592

Review 5.  Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP.

Authors:  Andreas Schober
Journal:  Cell Tissue Res       Date:  2004-07-28       Impact factor: 5.249

Review 6.  Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough.

Authors:  Matthias Löhle; Heinz Reichmann
Journal:  J Neurol Sci       Date:  2009-09-20       Impact factor: 3.181

7.  Evaluation of the probe 2',7'-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress.

Authors:  C P LeBel; H Ischiropoulos; S C Bondy
Journal:  Chem Res Toxicol       Date:  1992 Mar-Apr       Impact factor: 3.739

8.  A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Authors:  R S Burns; C C Chiueh; S P Markey; M H Ebert; D M Jacobowitz; I J Kopin
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

9.  Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.

Authors:  J A Javitch; R J D'Amato; S M Strittmatter; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

10.  The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice.

Authors:  P K Sonsalla; R E Heikkila
Journal:  Eur J Pharmacol       Date:  1986-10-07       Impact factor: 4.432

View more
  10 in total

1.  Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update.

Authors:  Juan Segura-Aguilar; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2015-01-29       Impact factor: 3.911

2.  Clavulanic Acid Attenuating Effect on the Diabetic Neuropathic Pain in Rats.

Authors:  Mahnoush Kolahdouz; Faranak Jafari; Farahnaz Falanji; Samad Nazemi; Mohammad Mohammadzadeh; Mehdi Molavi; Bahareh Amin
Journal:  Neurochem Res       Date:  2021-04-12       Impact factor: 3.996

3.  Clavulanic acid improves ethanol withdrawal symptoms in rats.

Authors:  Ehsan Mohebbi; Mehdi Molavi; Mohammad Mohammadzadeh; Hossein Hosseinzadeh; Bahareh Amin
Journal:  Iran J Basic Med Sci       Date:  2020-06       Impact factor: 2.699

4.  Clavulanic acid reduces rewarding, hyperthermic and locomotor-sensitizing effects of morphine in rats: a new indication for an old drug?

Authors:  Joseph A Schroeder; Nicholas G Tolman; Faye F McKenna; Kelly L Watkins; Sara M Passeri; Alexander H Hsu; Brittany R Shinn; Scott M Rawls
Journal:  Drug Alcohol Depend       Date:  2014-06-02       Impact factor: 4.492

5.  Neuroprotective role of thymoquinone against 1-methyl-4-phenylpyridinium-induced dopaminergic cell death in primary mesencephalic cell culture.

Authors:  Khaled S Radad; Mubarak M Al-Shraim; Mahmoud F Moustafa; Wolf-Dieter Rausch
Journal:  Neurosciences (Riyadh)       Date:  2015-01       Impact factor: 0.906

6.  Atractylenolide-I Protects Human SH-SY5Y Cells from 1-Methyl-4-Phenylpyridinium-Induced Apoptotic Cell Death.

Authors:  Sandeep Vasant More; Dong-Kug Choi
Journal:  Int J Mol Sci       Date:  2017-05-08       Impact factor: 5.923

7.  Effects of Clavulanic Acid on the Acquisition and Reinstatement Following Morphine-induced Conditioned Place Preference in Mice.

Authors:  Soghra Mehri; Seyed Saber Sajjadi; Seyed Meghdad Tabatabai; Hossein Hosseinzadeh
Journal:  Basic Clin Neurosci       Date:  2018-07-01

8.  Clavulanic Acid: A Novel Potential Agent in Prevention and Treatment of Scopolamine-Induced Alzheimer's Disease.

Authors:  Mahdieh Anoush; Zeinab Pourmansouri; Rafi Javadi; Benyamin GhorbanPour; Ali Sharafi; Hamed Mohamadpour; Iraj Jafari Anarkooli; Sina Andalib
Journal:  ACS Omega       Date:  2022-04-13

9.  Ceftriaxone and clavulanic acid induce antiallodynia and anti-inflammatory effects in rats using the carrageenan model.

Authors:  Abraham Ochoa-Aguilar; Rosa Ventura-Martinez; Marco Antonio Sotomayor-Sobrino; Ruth Jaimez; Ulises Coffeen; Ariadna Jiménez-González; Luis Gerardo Balcázar-Ochoa; Rafael Pérez-Medina-Carballo; Rodolfo Rodriguez; Ricardo Plancarte-Sánchez
Journal:  J Pain Res       Date:  2018-05-21       Impact factor: 3.133

10.  Upregulation of Glutamate Transporter 1 by Clavulanic Acid Administration and Attenuation of Allodynia and Hyperalgesia in Neuropathic Rats.

Authors:  Bahareh Amin; Mahmoud Avaznia; Reihaneh Noorani; Soghra Mehri; Hossein Hosseinzadeh
Journal:  Basic Clin Neurosci       Date:  2019-07-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.